UroGen Pharma (NASDAQ:URGN) Stock Rating Reaffirmed by HC Wainwright

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report issued on Tuesday, Benzinga reports. They presently have a $60.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 376.19% from the company’s current price.

Several other analysts have also weighed in on URGN. EF Hutton Acquisition Co. I raised UroGen Pharma to a “strong-buy” rating in a report on Monday. Guggenheim assumed coverage on UroGen Pharma in a report on Thursday, August 22nd. They issued a “buy” rating and a $40.00 price target for the company. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $48.38.

UroGen Pharma Stock Up 2.8 %

Shares of NASDAQ URGN opened at $12.60 on Tuesday. UroGen Pharma has a 12-month low of $10.60 and a 12-month high of $20.70. The stock has a fifty day moving average price of $13.52 and a 200 day moving average price of $14.37. The company has a current ratio of 8.15, a quick ratio of 7.93 and a debt-to-equity ratio of 3.23. The company has a market cap of $295.52 million, a P/E ratio of -3.71 and a beta of 1.11.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.09). The business had revenue of $21.85 million for the quarter, compared to analysts’ expectations of $23.69 million. Research analysts anticipate that UroGen Pharma will post -3.49 EPS for the current fiscal year.

Hedge Funds Weigh In On UroGen Pharma

Institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP boosted its position in UroGen Pharma by 49.3% during the 4th quarter. Wellington Management Group LLP now owns 104,600 shares of the company’s stock valued at $1,569,000 after purchasing an additional 34,537 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of UroGen Pharma by 65.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 5,903 shares of the company’s stock worth $89,000 after acquiring an additional 2,328 shares during the last quarter. Oak Ridge Investments LLC bought a new position in shares of UroGen Pharma during the first quarter worth about $918,000. BNP Paribas Financial Markets increased its holdings in shares of UroGen Pharma by 73.1% in the 1st quarter. BNP Paribas Financial Markets now owns 39,795 shares of the company’s stock worth $597,000 after acquiring an additional 16,799 shares during the period. Finally, Vanguard Group Inc. lifted its position in UroGen Pharma by 14.3% in the 1st quarter. Vanguard Group Inc. now owns 194,966 shares of the company’s stock valued at $2,924,000 after purchasing an additional 24,367 shares during the last quarter. 91.29% of the stock is owned by institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.